Physician profile
Toby R Smith
NPI 1932190360
$16,918.27
in general payments reported to CMS, 2019-2025
35 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,299 · 2021: $1,336 · 2022: $1,091 · 2023: $959 · 2024: $275 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,516 · Travel and Lodging: $2,036 · Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,516.24 |
| Travel and Lodging | $2,035.97 |
| Food and Beverage | $886.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,986.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,163.61 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,081.52 | 2019-2025 | Trelegy Ellipta |
| Medtronic, INC. | $922.75 | 2023-2024 | Illumisite, Arcpoint |
| Astrazeneca Pharmaceuticals Lp | $535.19 | 2019-2023 | Symbicort, Fasenra |
| Insmed, INC. | $479.64 | 2019-2023 | Arikayce |
| Grifols USA, LLC | $430.96 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $243.44 | 2019-2020 | |
| Inspire Medical Systems, INC. | $241.73 | 2019-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $153.81 | 2019-2022 | |
| Davol INC. | $149.41 | 2025 | Progel Applicator Spray Tips |
| Electromed, INC. | $149.29 | 2021-2022 | |
| Genzyme Corporation | $136.96 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $98.07 | 2020-2022 | |
| United Therapeutics Corporation | $89.93 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $84.87 | 2019-2021 | |
| Pfizer INC. | $84.62 | 2020-2022 | |
| Harmony Biosciences LLC | $79.24 | 2020-2023 | Wakix |
| Genentech USA, INC. | $78.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $76.25 | 2021-2022 | |
| Pulmonx Corporation | $70.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.93 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $63.90 | 2021-2022 | |
| Mylan Specialty L.P. | $59.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.61 | 2019-2020 | |
| Philips North America LLC | $50.07 | 2019 | |
| Erbe USA INC | $50.00 | 2025 | Cryo2 |
| Takeda Pharmaceuticals U.S.A., INC. | $49.81 | 2020-2022 | |
| Portola Pharmaceuticals, LLC | $47.15 | 2019 | |
| Vapotherm INC | $32.12 | 2022 | |
| Axsome Therapeutics, INC. | $25.44 | 2023 | Sunosi |
| Apria Healthcare LLC | $23.23 | 2021 | |
| Gilead Sciences, INC. | $22.96 | 2022 | |
| Baxter Healthcare | $19.47 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.